One thing is certain: if Whitworth’s Relational Investors wanted a new board member who’ll advocate for an early “cash-out exit, at essentially any cost” to all the other stakeholders, and possibly even the smaller common shareholders. . . in SGP Ex-CFO Bob Bertolini, they’ve likely found their man (solely in my opinion — given that he likely will personally pocket something like $120 million, all-in, for his part in busting-up old Schering-Plough).

In an unusual twist, see the link above for much more — about Bertolini’s continuing “confidentiality and non-use obligations” in favor of New Merck — each arguably not allowing him to participate in many Genzyme board discussions or decisions — and, in perpetuity, it would seem.

Namaste — should be interesting to watch it all unfold.